دورية أكاديمية
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
| العنوان: | Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY. |
|---|---|
| المؤلفون: | Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim HD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Yook JH; Department of Surgery, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea., Park YK; Department of Surgery, Chonnam National University Medical School, Hwasun, Republic of Korea., Lee JS; Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim YW; Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea., Kim JY; Division of Hemato-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea., Ryu MH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Chung IJ; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeonnam, Republic of Korea., Kim IH; Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Oh SC; Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea., Park YS; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Cheong JH; Department of Surgery, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Jeong O; Department of Surgery, Chonnam National University Medical School, Hwasun, Republic of Korea., Heo MH; Division of Hemato-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea., Kim HK; Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea., Park C; Department of Surgery, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Yoo CH; Department of Surgery, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Republic of Korea., Kang SY; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea., Zang DY; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea., Jang YJ; Department of Surgery, Korea University Guro Hospital, Seoul, Republic of Korea., Sul JY; Department of Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea., Kim JG; Department of Internal Medicine, Kyungpook National University, Daegu, Republic of Korea., Kim BS; Department of Surgery, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea., Beom SH; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Hwang JE; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeonnam, Republic of Korea., Ryu SW; Department of Surgery, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea., Kook MC; Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea., Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim H; Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea., Yoo MW; Department of Surgery, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea., Lee NS; Department of Internal Medicine, Soon Chun Hyang University Hospital, Seoul, Republic of Korea., Lee SH; Department of Surgery, Kosin University Gospel Hospital, Busan, Republic of Korea., Noh SH; Department of Surgery, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jul 12, pp. JCO2302167. Date of Electronic Publication: 2024 Jul 12. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مستخلص: | Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia. |
| سلسلة جزيئية: | ClinicalTrials.gov NCT01515748 |
| تواريخ الأحداث: | Date Created: 20240712 Latest Revision: 20240712 |
| رمز التحديث: | 20240713 |
| DOI: | 10.1200/JCO.23.02167 |
| PMID: | 38996201 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.23.02167 |